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cer pain [3]. The reviewer started to search for randomised
controlled trials. Surprisingly his search strategy retrieved
no randomised trials. Indeed Quigley moved on consider-
ing the results of observational studies. He found 23 case
reports and series, 15 retrospective patient records review
and 14 prospective uncontrolled studies. The majority of
the reports used morphine as a first-line opioid and the
most frequently used second-line opioid was methadone.
All reports, except for one, concluded that opioid switch-
ing is a useful clinical manoeuvre for improving pain con-
trol and/or reducing opioid-related side effects.
In the “implication for practice” section the authors
concluded that a robust evidence base for the practice of
opioid switching does not exist.
The poor designs
Observational studies share a similar purpose with ran-
domised controlled trials: to test descriptive causal
hypotheses about manipulable causes [4]. However, in
observational studies, researchers have little control over
confounding variables (i.e., worsening of the disease) and
the delivery of the intervention (i.e., switch of route).
Indeed observational designs are intrinsically weak evalu-
ative designs, as secular trends and sudden changes make it
difficult to attribute observed changes to the intervention.
While observational studies could contribute to the
understanding of better pain management, the unaccount-
ed biases that are inherent in the study design increase the
uncertainty and significantly hamper the judgement of a
direct causal relationship between the intervention and the
outcome. Many authors of included studies claimed in
their conclusions that the switched opioid can rapidly pro-
duce an improvement in patient pain. For example, Bruera
et al. stated: “We conclude that custom made capsules and
suppositories of high-dose methadone are an effective,
safe and low-cost alternative in patients receiving high
doses of parenteral opioids” [5]. This conclusion could be
criticised for being overzealous in the inference of causal-
ity due to potential rival hypotheses that might have
explained findings. These threats to internal validity are so
plausible that Cook and Campbell describe the results of
uncontrolled trials as “generally uninterpretable” [4].
They also argue that investigators using such quasi-exper-
imental methods need to rule out all plausible rival
hypotheses before any causal relationship can be inferred.
We believe that there are many plausible rival hypotheses
that could also explain the study results that have not been
excluded by the investigators (e.g., route of administra-
tion, co-interventions such as anticonvulsants).
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Reading a systematic review is often an educational expe-
rience that makes you think about things in a different
way. This review from The Cochrane Library highlights
the disconcerting gap between what we would like to
know and how much we actually know in a relevant clin-
ical problem. Pain is a common dimension of cancer dis-
ease: at least two thirds of patients experience pain at
some time during the course of their illness [1]. In at least
10% of these patients the pain is difficult to control. Their
pain often falls into two categories: it responds poorly to
opioids or it is episodic and breaks through despite back-
ground opioid analgesia. In both cases a possible solution
is opioid switch. What do we know about its efficacy?
Facing the lack of research
Most patients with cancer develop pain requiring strong
opioids. Morphine is the drug of choice, as recommended
by the World Health Organization, for the management of
moderate to severe cancer-related pain [1]. However, a
significant minority do not achieve adequate analgesia
with morphine. In this group of patients, intolerable side
effects such as vomiting, delirium and myoclonus pre-
clude dose escalation. It has been observed clinically that
switching from one opioid, which has failed to control
pain or caused intolerable side effects, to an alternative
opioid can result in improved tolerability, pain control, or
both. Some clinicians claim that some patients need to
change the type of strong opioid at least once to achieve
optimal pain control with acceptable side effects [2].
In 2004 Quigley published a Cochrane systematic
review with the aim of investigating the usefulness of opi-
oid rotation/switching/substitution for patients with can-
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When can observational studies be helpful?
Case series are used to generate hypotheses about the
causal relationship between two variables or to assess the
feasibility and the safety of an emerging technology or
treatment. Hundreds of case series have been published up
to now to test, for instance, the safety and the feasibility of
tomotherapy, a new radiation treatment modality, or the
telemanipulator da Vinci, a robotic surgery. Randomised
controlled trials comparing the new technology with the
standard intervention are now necessary before imple-
menting the technology as a routine treatment.
Observational prospective controlled studies can be
used to assess the effectiveness of interventions on long-
term outcomes or rare events that are not suitable for eval-
uation within experimental studies. An example could be
the effect of methadone maintenance treatment for heroin-
dependent subjects on all-cause mortality.
Observational cohort studies could also be used to
assess the effectiveness of intervention in clinical settings
where randomisation is not practically feasible nor ethi-
cally acceptable; for example randomised controlled trials
are not ethically feasible to assess the effectiveness of
bilateral prophylactic mastectomy or bilateral prophylactic
salpingo-oophorectomy as a risk reduction strategy for
women with BRCA germline mutation.
Feasible randomised controlled trials
Effectiveness of opioid therapy for pain relief in cancer
patients could definitely be assessed by randomised con-
trolled trials. For example, the Cochrane review that assess-
es the efficacy of oral morphine for cancer pain includes 45
randomised controlled trials with 2061 subjects [6], while
the Cochrane review on opioids for the management of
episodic pain in cancer patients includes 4 randomised dou-
ble-blind controlled trials with 393 participants [7].
Is this evidence sufficient? Despite the importance of
cancer pain control in patients’ agendas, we have very lit-
tle and often sub-optimal evidence. The median number of
patients enrolled in randomised trials of primary anal-
gesics (NSAIDs, opioids and adjuvants) was 70 or fewer.
Furthermore, these trials constitute about 1% of the pub-
lished literature on cancer pain, enrol 1 in 10 000 patients
at risk for cancer pain in developed countries, are often
heterogeneous and are often of poor methodological qual-
ity [8]. We do not know which route of administration is
better, which drug to select first, which one as a second
line or when to use combinations. Nothing about children.
Methodologically sound trials with cancer pain relief as a
primary outcome are required in patients with well defined
disease and pain.
The clinicians and researchers engaged with cancer
pain should weigh the words that Doug Altman wrote more
than ten years ago in an editorial which is still dramatical-
ly current: “We need less research, better research, and
research done for the right reasons” [9].
Clinician’s point of view
G.F. Gensini, R. Gusini
To avoid pain is a universal right.
According to the World Health Organization the con-
sumption per capita of morphine is one of the more reli-
able pointers of the quality of the analgesic therapy for
cancer pain and other strict physical suffering.
Patient studies have contributed largely to the
decrease in cancer death rates in the world. Clinical stud-
ies have also led to better pain control methods, such as
continuous pain-medication infusion pumps, first devel-
oped in the early 1980s, but the problem of cancer pain
control represents one of the main problems in the man-
agement of cancer patients, particularly in minorities,
women and the elderly.
Unfortunately, it shares with pain control in general the
difficulties in precisely evaluating the efficacy and the
appropriateness of treatment strategies. This stems from
several reasons, including: difficulties in distinguishing
the different causes and mechanisms of cancer pain; the
need for a multidisciplinary approach including general
practitioners, specialists who may be able to care for
patients who have difficult pain problems including pallia-
tive care physicians, clinical nurse specialists (CNS), pain
relief anaesthetists, pharmacists, psychologists and phys-
iotherapists; and the difficulties in assessing the precise
contribution of the individual drugs, most often adminis-
tered simultaneously.
More high-quality experimental studies are urgently
needed, with more complete descriptions of pain,
improved statistical reporting, controls over adequacy of
and compliance to the intervention, use of single inter-
ventions, and use of more complex measures of affective
outcomes.
Only in this way will we be able to obtain good-quali-
ty evidence to translate into good-quality Evidence-Based
Guidelines.
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